`
`IN BU.SINES$ FOR LIFE
`
`TECHNICAL MEMORANDUM
`
`LATE STAGE PHARM. & DEVICE DEV
`
`DATE:
`TO:
`
`November 19, 2007
`
`Novartis
`
`FROM:
`SUBJECT: Technical Assessment of
`
`Sterilization of Lucentis Pre-filled Syringe
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 1 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)02022271
`
`Novartis Exhibit 2148.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 2 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)02022271
`
`Novartis Exhibit 2148.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Page 3 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION , SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)02022271
`
`Novartis Exhibit 2148.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Page 4 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION , SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)02022271
`
`Novartis Exhibit 2148.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Page 5 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)02022271
`
`Novartis Exhibit 2148.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Page 6 of 6
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)02022271
`
`Novartis Exhibit 2148.006
`Regeneron v. Novartis, IPR2021-00816
`
`